Our vision is for a radically new omics measurement platform applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase
Inhibitor (TKI) resistance associated to Epidermal Growth Factor Receptor (EGFR) mutations.

The detection of EGFR mutations will be made possible by the new omics measurement platform enabled by fast, high-throughput, bio-sensing technology, applicable for measuring metabolomics, proteomics and transcriptomics from plasma, EVs and tumor cells.